Form 8-K

8-K — Doximity, Inc.

Accession: 0001516513-26-000038

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001516513

SIC: 7371 (SERVICES-COMPUTER PROGRAMMING SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — docs-20260806.htm (Primary)

EX-99.1 (doximity-2026630xex991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: docs-20260806.htm · Sequence: 1

docs-20260806

0001516513FALSE00015165132026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________________________________________________________

FORM 8-K

_________________________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

_________________________________________________________________________________________________________________

Doximity, Inc.

(Exact Name of Registrant as Specified in Its Charter)

_________________________________________________________________________________________________________________

Delaware

001-40508

27-2485512

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

500 3rd St.

Suite 510

San Francisco, CA 94107

(Address of principal executive offices, including zip code)

(650) 549-4330

(Registrant's telephone number, including area code)

_______________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, $0.001 par value per share

DOCS

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 – Results of Operations and Financial Condition

On August 6, 2026, Doximity, Inc. (“Doximity”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information provided in this Item 2.02 of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 – Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description

99.1

Press Release entitled “Doximity Announces Fiscal 2027 First Quarter Financial Results dated August 6, 2026”

104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 6, 2026

DOXIMITY, INC.

By:

/s/ Matthew Sonefeldt

Matthew Sonefeldt

Chief Financial Officer

EX-99.1

Filename: doximity-2026630xex991.htm · Sequence: 2

Document

Exhibit 99.1

Doximity Announces Fiscal 2027 First Quarter Financial Results

Total revenues of $156.6 million, up 7% year-over-year

Net income of $24.3 million, margin of 16%

Adjusted EBITDA of $74.8 million, margin of 48%

SAN FRANCISCO, Calif., August 6, 2026 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 first quarter ended June 30, 2026.

“We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. "In Q1 we had accelerated revenue growth along with workflow active prescriber growth of more than 30% year-over-year and AI Search query growth of over 25% quarter-over-quarter.”

Fiscal 2027 First Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended June 30, 2025.

•Revenue: Revenue of $156.6 million, versus $145.9 million, an increase of 7% year-over-year.

•Net income and non-GAAP net income: Net income of $24.3 million, versus $53.3 million, representing a margin of 15.5%, versus 36.5%. Non-GAAP net income of $55.0 million, versus $71.9 million, representing a margin of 35.1%, versus 49.2%.

•Adjusted EBITDA: Adjusted EBITDA of $74.8 million, versus $79.8 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 47.7%, versus 54.7%.

•Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.13, versus $0.27, while non-GAAP diluted net income per share was $0.29, versus $0.36.

•Operating cash flow and free cash flow: Operating cash flow of $42.0 million, versus $62.1 million, a decrease of 32% year-over-year, and free cash flow of $39.6 million, versus $60.1 million, a decrease of 34% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal second quarter ending September 30, 2026 as follows:

•Revenue between $170 million and $171 million.

•Adjusted EBITDA between $80.5 million and $81.5 million.

Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows:

•Revenue between $671 million and $681 million.

•Adjusted EBITDA between $309 million and $329 million.

For more detailed financial commentary, please refer to the “Modeling Considerations” appendix in our prepared remarks.

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The recorded webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements are all statements other than statements of historical fact, and specifically include statements regarding guidance and future business and financial results. These statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Perry Gold

ir@doximity.com

Media Contact:

Richard George

pr@doximity.com

DOXIMITY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

June 30, 2026 March 31, 2026

Assets

Current assets:

Cash and cash equivalents $ 273,604 $ 219,178

Marketable securities 414,185 529,423

Accounts receivable, net 177,575 144,783

Prepaid expenses and other current assets 48,614 50,880

Total current assets 913,978 944,264

Property and equipment, net 19,243 18,080

Deferred income tax assets 23,839 31,984

Operating lease right-of-use assets 6,752 7,140

Intangible assets, net 33,385 35,325

Goodwill 84,973 84,973

Other assets 1,675 1,921

Total assets $ 1,083,845 $ 1,123,687

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable $ 6,494 $ 4,009

Accrued expenses and other current liabilities 32,666 42,804

Deferred revenue, current 109,061 106,050

Operating lease liabilities, current 2,142 2,110

Total current liabilities 150,363 154,973

Deferred revenue, non-current 37 400

Operating lease liabilities, non-current 7,531 8,075

Other liabilities, non-current 9,844 9,402

Total liabilities 167,775 172,850

Stockholders' Equity

Preferred stock — —

Common stock 180 183

Additional paid-in capital 1,035,282 1,001,688

Accumulated other comprehensive income (loss) (348) 28

Accumulated deficit (119,044) (51,062)

Total stockholders’ equity

916,070 950,837

Total liabilities and stockholders’ equity $ 1,083,845 $ 1,123,687

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended June 30,

2026 2025

Revenue $ 156,618 $ 145,913

Cost of revenue(1)

23,692 15,793

Gross profit 132,926 130,120

Operating expenses(1):

Research and development 38,477 26,799

Sales and marketing 45,049 36,365

General and administrative 15,756 12,439

Total operating expenses 99,282 75,603

Income from operations 33,644 54,517

Other income, net 6,719 9,630

Income before income taxes 40,363 64,147

Provision for income taxes 16,048 10,827

Net income $ 24,315 $ 53,320

Net income per share attributable to Class A and Class B common stockholders:

Basic $ 0.13 $ 0.28

Diluted $ 0.13 $ 0.27

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic 182,569 187,984

Diluted 191,169 201,158

(1) Costs and expenses include stock-based compensation expense as follows (in thousands):

Three Months Ended June 30,

2026 2025

Cost of revenue $ 3,192 $ 2,980

Research and development 15,559 6,649

Sales and marketing 12,425 7,710

General and administrative 5,576 4,526

Total stock-based compensation expense $ 36,752 $ 21,865

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended June 30,

2026 2025

Cash flows from operating activities

Net income $ 24,315 $ 53,320

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 4,287 2,794

Stock-based compensation, net of amounts capitalized 36,752 21,865

Non-cash lease expense 387 450

Accretion of discount on marketable securities, net (568) (2,488)

Amortization of deferred contract costs 4,300 3,896

Other (338) (408)

Changes in operating assets and liabilities:

Accounts receivable (33,334) (13,381)

Prepaid expenses and other assets 9,125 (4,234)

Deferred contract costs (2,642) (1,965)

Accounts payable, accrued expenses and other liabilities (2,433) (165)

Deferred revenue 2,648 2,973

Operating lease liabilities (512) (556)

Net cash provided by operating activities 41,987 62,101

Cash flows from investing activities

Purchases of property and equipment (62) —

Internal-use software development costs (2,322) (1,966)

Purchases of marketable securities (14,746) (139,934)

Maturities of marketable securities 126,071 144,579

Sales of marketable securities 4,049 —

Net cash provided by investing activities 112,990 2,679

Cash flows from financing activities

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

3,080 2,398

Taxes paid related to net share settlement of equity awards (6,974) (11,927)

Repurchase of common stock (91,633) (122,355)

Payment of contingent consideration related to a business combination (5,024) (5,249)

Net cash used in financing activities (100,551) (137,133)

Net increase (decrease) in cash and cash equivalents 54,426 (72,353)

Cash and cash equivalents, beginning of period 219,178 209,614

Cash and cash equivalents, end of period

$ 273,604 $ 137,261

Supplemental disclosures of cash flow information

Cash paid for taxes, net of refunds

$ 3,990 $ 4,978

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

•Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.

•Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

•Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment, purchases of intangible assets, and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

•Net revenue retention rate: Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

•Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business and the value we create for large customers, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

•Quarterly unique active providers using our workflow tools: Quarterly unique active providers1 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely login and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times.

1 Providers are health care professionals with clinical / prescribing roles specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetist (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three Months Ended June 30,

2026 2025

(unaudited)

(in thousands, except percentages)

Net income $ 24,315 $ 53,320

Adjusted to exclude the following:

Acquisition and other related expenses — 428

Stock-based compensation 36,752 21,865

Depreciation and amortization 4,287 2,794

Provision for income taxes 16,048 10,827

Change in fair value of contingent earn-out consideration liability 90 168

Other income, net (6,719) (9,630)

Adjusted EBITDA $ 74,773 $ 79,772

Revenue $ 156,618 $ 145,913

Net income margin 15.5 % 36.5 %

Adjusted EBITDA margin 47.7 % 54.7 %

Three Months Ended June 30,

2026 2025

(unaudited)

(in thousands)

Net cash provided by operating activities $ 41,987 $ 62,101

Purchases of property and equipment (62) —

Internal-use software development costs (2,322) (1,966)

Free cash flow $ 39,603 $ 60,135

Other cash flow components:

Net cash provided by investing activities $ 112,990 $ 2,679

Net cash used in financing activities $ (100,551) $ (137,133)

Three Months Ended June 30,

2026

2025

(unaudited)

(in thousands, except per share data and percentages)

GAAP cost of revenue $ 23,692 $ 15,793

Adjusted to exclude the following:

Stock-based compensation (3,192) (2,980)

Amortization of acquired intangibles (935) —

Non-GAAP cost of revenue $ 19,565 $ 12,813

GAAP gross profit $ 132,926 $ 130,120

Adjusted to exclude the following:

Stock-based compensation 3,192 2,980

Amortization of acquired intangibles 935 —

Non-GAAP gross profit $ 137,053 $ 133,100

GAAP gross margin 84.9 % 89.2 %

Non-GAAP gross margin 87.5 % 91.2 %

GAAP research and development expense $ 38,477 $ 26,799

Adjusted to exclude the following:

Stock-based compensation (15,559) (6,649)

Non-GAAP research and development expense $ 22,918 $ 20,150

GAAP sales and marketing expense $ 45,049 $ 36,365

Adjusted to exclude the following:

Stock-based compensation (12,425) (7,710)

Amortization of acquired intangibles (1,005) (1,002)

Change in fair value of contingent earn-out consideration liability (90) (168)

Non-GAAP sales and marketing expense $ 31,529 $ 27,485

GAAP general and administrative expense $ 15,756 $ 12,439

Adjusted to exclude the following:

Acquisition and other related expenses — (428)

Stock-based compensation (5,576) (4,526)

Non-GAAP general and administrative expense $ 10,180 $ 7,485

GAAP operating expense $ 99,282 $ 75,603

Adjusted to exclude the following:

Acquisition and other related expenses — (428)

Stock-based compensation (33,560) (18,885)

Amortization of acquired intangibles (1,005) (1,002)

Change in fair value of contingent earn-out consideration liability (90) (168)

Non-GAAP operating expense $ 64,627 $ 55,120

Three Months Ended June 30,

2026

2025

(unaudited)

(in thousands, except per share data and percentages)

GAAP operating income $ 33,644 $ 54,517

Adjusted to exclude the following:

Acquisition and other related expenses — 428

Stock-based compensation 36,752 21,865

Amortization of acquired intangibles 1,940 1,002

Change in fair value of contingent earn-out consideration liability 90 168

Non-GAAP operating income $ 72,426 $ 77,980

GAAP net income $ 24,315 $ 53,320

Adjusted to exclude the following:

Acquisition and other related expenses — 428

Stock-based compensation 36,752 21,865

Amortization of acquired intangibles 1,940 1,002

Change in fair value of contingent earn-out consideration liability 90 168

Income tax effect of non-GAAP adjustments (1)

(8,144) (4,927)

Non-GAAP net income $ 54,953 $ 71,856

Non-GAAP net income margin 35.1 % 49.2 %

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic 182,569 187,984

Diluted 191,169 201,158

Non-GAAP net income per share attributable to Class A and Class B stockholders:

Basic $ 0.30 $ 0.38

Diluted $ 0.29 $ 0.36

(1) For the three months ended June 30, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 06, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

Doximity, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-40508

Entity Tax Identification Number

27-2485512

Entity Address, Address Line One

500 3rd St.

Entity Address, Address Line Two

Suite 510

Entity Address, City or Town

San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94107

City Area Code

650

Local Phone Number

549-4330

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A common stock, $0.001 par value per share

Trading Symbol

DOCS

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001516513

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration